SteelPeak Wealth’s ADMA Biologics ADMA Stock Holding History

SteelPeak Wealth’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-23,569	Closed	-$471K	–	568
2024 Q3	$471K	Buy	+23,569	New	+$367K	0.02%	328

Other funds holding ADMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

SteelPeak Wealth's ADMA Position: Q4 2024 in Review

SteelPeak Wealth sold out of ADMA Biologics (ADMA) in Q4 2024, closing a stake of 23,569 shares — an estimated $471K sold.

SteelPeak Wealth first reported a position in ADMA in Q3 2024 and held it in 1 quarter. The position peaked at $471K in Q3 2024. 322 funds tracked by Wall St. Rank hold ADMA as of Q4 2024.

SteelPeak Wealth reported no remaining ADMA Biologics position as of Q4 2024 after selling out during the quarter.
SteelPeak Wealth sold 23,569 ADMA Biologics shares in Q4 2024, an estimated $471K.
SteelPeak Wealth first reported a position in ADMA Biologics in Q3 2024 and held it in 1 quarter.
SteelPeak Wealth's ADMA Biologics position peaked at $471K in Q3 2024.
322 funds tracked by Wall St. Rank held ADMA Biologics as of Q4 2024.

Based on SteelPeak Wealth's 13F filing for Q4 2024, filed 23 Jan 2025.